Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923727 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer
A Phase 1 study, sponsored by ImaginAb.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01923727 is a Phase 1 study that has completed, run by ImaginAb. The registered enrollment target is 38 participants.
The verdict
NCT01923727, a Phase 1 study, has completed, sponsored by ImaginAb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a Phase I/IIa study evaluating the safety and feasibility of \[89Zr\]Df-IAB2M as an immunoPET tracer for metastatic prostate cancer. Individuals participating in this study will have a FDG PET scan, as well as four (4) PET scans (over a 3 day period) following the injection of \[89Zr\]Df-IAB2M PET tracer. Three different dosing levels will be explored. The purpose of the study is to demonstrate the safety of \[89Zr\]Df-IAB2M, ability to detect prostate cancer, and optimal time point and dose level for imaging.
Interventions
- BIOLOGICAL [89Zr]Df-IAB2M
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01923727
The ClinicalTrials.gov registry entry for NCT01923727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImaginAb, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [89Zr]Df-IAB2M is the first listed.
NCT01923727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01923727 about?
NCT01923727 is a clinical study titled "Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer". This is a Phase I/IIa study evaluating the safety and feasibility of \[89Zr\]Df-IAB2M as an immunoPET tracer for metastatic prostate cancer. Individuals participating in this study will have a FDG PET scan, as well as four (4) PET scans (over a 3 day period) following the injection of \[89Zr\]Df-IAB...
What is the current status of trial NCT01923727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2013-08. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01923727?
The interventions under investigation include: [89Zr]Df-IAB2M (BIOLOGICAL).
Who is sponsoring clinical trial NCT01923727?
This trial is sponsored by ImaginAb, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.